Medical Oncology Branch and Affiliates
Head, Early Clinical Trials Development
Office of the Director
Division of Cancer Treatment and Diagnosis
National Cancer Institute
9000 Rockville Pike
Building 31, Room 3A44
Bethesda, MD 20892
Phone: 301-435-0517
Fax: 301-496-0826
kummars@mail.nih.gov
Dr. Kummar received her medical degree from Lady Hardinge Medical College, New Delhi, India, and her internal medicine residency training from Emory University, Atlanta, GA. Upon completion of her fellowship training in medical oncology and hematology from the National Institutes of Health, Bethesda, Maryland, she joined Yale Cancer Center, Yale University, New Haven, CT, as an assistant professor in medical oncology. In 2004, Dr. Kummar moved back to NCI and is currently head of the Early Clinical Trials Development in the Office of the Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute. Her research interests focus on the early development (Phase I/II trials) of novel therapies for cancer.
Dr. Kummar's Clinical Trial(s):
NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with colorectal cancer, head and neck cancer, lymphoma, sarcoma, or solid tumors. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.
- Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
NCI-13-C-0105, NCT01827384
|
- A Phase I Trial of Weekly Indenoisoquinoline LMP400 in Adults With Relapsed Solid Tumors and Lymphomas
NCI-13-C-0080, NCT01794104
|
- A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma
NCI-13-C-0044, NCT01755195
|
- A Phase I Study of Single-agent MK-1775, a Wee1 Inhibitor, in Patients With Advanced Refractory Solid Tumors
NCI-13-C-0032, NCT01748825
|
- A Phase I and Pharmacokinetic Single-agent Study of Romidepsin in Patients With Lymphomas, Chronic Lymphocytic Leukemia, Select Solid Tumors, and Varying Degrees of Liver Dysfunction
NCI-12-C-0177, NCT01638533
|
- Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors
NCI-12-C-0009, NCT01468922
|
- A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression
NCI-11-C-0200, NCT01391962
|
- A Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma
NCI-11-C-0150, NCT01581541
|
- Pilot Study of the Combination of MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor, in Patients With Advanced Colorectal Carcinoma
NCI-11-C-0117, NCT01333475
|
- Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
NCI-11-C-0061, NCT01273168
|
- A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
NCI-11-C-0060, NCT01273155
|
- Phase I Study of the HSP-90 Inhibitor, AT13387, in Adults With Refractory Solid Tumors
NCI-11-C-0029, NCT01245218
|
- A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
NCI-10-C-0056, NCT01051635
|
- Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
NCI-09-C-0192, NCT00942877
|
- A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux®) in EGFR Expressing Metastatic Colorectal Cancer (CRC)
NCI-06-C-0164, NCT00326495
|
Videocast/Podcast Details:
The quality of these videocasts is dependent on the speed of your Internet connection. Many videocasts are streamed directly to your computer by software on the NIH VideoCasting Web site. Others require that you have a standalone player installed on your computer to handle the streaming. If you do not have a standalone player installed or if you are having problems viewing the videocast, please visit http://videocast.nih.gov/faq/.
|
CC Grand Rounds: (1) PARP Inhibitors: How Successful Have We Been in Modulating DNA Damage? (2) The Evolving Role of PARP Inhibitors in Breast and Ovarian Cancers
Speaker(s): Shivaani Kummar, MD, Head, Early Clinical Trials Development, Office of the Director, Division of Cancer Treatment and Diagnosis, NCI
Elise C. Kohn, MD, Head, Medical Ovarian Cancer Clinic, and Head, Molecular Signaling Section, Medical Oncology Branch, Center for Cancer Research, NCI
March 23, 2011
63 minutes
http://videocast.nih.gov/launch.asp?16541
|
Some of the resources above require the use of a standalone player: Download Free RealPlayer 